| [1] |
Lewington VJ. Cancer therapyusing bone-seeking isotopes[J]. Phys Med Biol, 1996, 41(10):2027~2042.
|
| [2] |
Pusuwan P, Chaiwatanarat T, Chaudakshetrin P, et al.Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases[J]. J Med Assoc Thai, 1996, 79(9):579~584.
|
| [3] |
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double-blind placebo-controlled clinical trial[J]. J Clin Oncol, 1998, 16(4):1574~1581.
|
| [4] |
Resche JF, Catal A, Pecking P, et al. A Dose-controlled study of 153 Sm-ethylenediaminetetramethylene-phosphonate (EDTMP) in the treatment of patients with painful bone metastases[J]. Eur J Cancer, 1997,33(10):1583~1591.
|
| [5] |
Bruland OS, Skretting A, Solheim OP, et al. Targeted radlotherapy of osteosarcoma using 153 Sm-EDTMP:A new promising approach[J]. Acta Oncol, 1996, 35(3):381~384.
|
| [6] |
Alberts AS, Smit BJ, Louw WK, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone[J]. Radiother Oncol, 1997, 43(2):175~179.
|
| [7] |
Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylenediaminetetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. Eur J Nucl Med, 1999, 26(1):2~7.
|
| [8] |
McEwan AJ. Unsealed source therapy of painful bone metastases:an update[J]. Semin Nucl Med, 1997, 27(2):165~182.
|
| [9] |
Cameron PJ, Klemp PF, Martindale AA, et al. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy[J]. Nucl Med Commun, 1999, 20(7):609~615.
|